All
Individualized Treatment Needed for Relapsed, Refractory Multiple Myeloma
October 10th 2017Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.
Smartphone App Aims to Conquer Social Isolation of Young Cancer Survivors
October 9th 2017All too often for these individuals, a once-normal social life is thrown to the wayside and replaced with doctors’ appointments and treatment regimens. Friends and family members may not fully understand what their loved one is going through. A new app is here to help.
Expert Gives an Overview of New Drugs to Treat AML
October 9th 2017For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.